Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177 [PMID: 25083091 DOI: 10.3748/wjg.v20.i27.9170]
Corresponding Author of This Article
Carlos Taxonera, MD, PhD, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040 Madrid, Spain. carlos.taxonera@salud.madrid.org
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2014; 20(27): 9170-9177 Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis
Carlos Taxonera, David Olivares, Juan L Mendoza, Manuel Díaz-Rubio, Enrique Rey
Carlos Taxonera, David Olivares, Juan L Mendoza, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, 28040 Madrid, Spain
Carlos Taxonera, David Olivares, Juan L Mendoza, Manuel Díaz-Rubio, Enrique Rey, Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
Manuel Díaz-Rubio, Enrique Rey, Department of Gastroenterology, Hospital Clínico San Carlos, 28040 Madrid, Spain
Author contributions: Taxonera C performed the research, analyzed the data, designed the research study and wrote the paper; Olivares D collected and analyzed the data and designed the research; Mendoza JL performed the research and critical review of the manuscript; Díaz-Rubio M and Rey E designed the research study and critical review of the manuscript.
Correspondence to: Carlos Taxonera, MD, PhD, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040 Madrid, Spain. carlos.taxonera@salud.madrid.org
Telephone: +34-91-3303713 Fax: +34-91-3303785
Received: November 13, 2013 Revised: January 24, 2014 Accepted: April 2, 2014 Published online: July 21, 2014 Processing time: 250 Days and 17.1 Hours
Core Tip
Core tip: Infliximab dose intensification to counteract loss of response is well established in the management of patients with Crohn’s disease (CD). In ulcerative colitis, the need for infliximab dose intensification is less well established. The study compares for the first time the need for infliximab dose intensification for ulcerative colitis and CD in the same clinical setting. The need for infliximab dose intensification was significantly higher in patients with ulcerative colitis compared to patients with Crohn’s disease. The drug administration costs were also higher in patients with ulcerative colitis. Our data provide a rational basis for economic planning in patients with ulcerative colitis selected for anti-tumor necrosis factor-α therapy.
